Chronic Lymphocytic Leukemia

>

Latest News

Findings from a phase 1a/1b trial highlight that treatment with NX-5948 appears to be tolerable among patients with relapsed/refractory B-cell malignancies.
NX-5948 Receives FDA Fast Track Designation in Relapsed/Refractory CLL/SLL

January 18th 2024

Findings from a phase 1a/1b trial highlight that treatment with NX-5948 appears to be tolerable among patients with relapsed/refractory B-cell malignancies.

Investigators report favorable overall survival among patients with chronic lymphocytic leukemia who receive ibrutinib/venetoclax over FCR.
MRD-Directed Ibrutinib/Venetoclax Results in PFS Benefit in CLL

January 16th 2024

Findings from a retrospective study highlight an increase in the use of targeted agents like ibrutinib from 1998 to 2020 for American military veterans with chronic lymphocytic leukemia.
Targeted Therapies Prolong Survival in Military Veteran CLL Population

January 10th 2024

Patients with chronic lymphocytic leukemia in the ALPINE study previously treated with BTK inhibitors are likely to remain sensitive to other BTK-targeting agents, says Jennifer Brown, MD, PhD.
Zanubrutinib/Ibrutinib in CLL Yields Low BTK/PLCG2 Mutation Incidence

December 29th 2023

Pirtobrutinib Effective in Heavily Pretreated BTK–Mutated CLL
Pirtobrutinib Effective in Heavily Pretreated BTK–Mutated CLL

December 28th 2023

Video Series
Video Interviews
Podcasts

More News